A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.

about

A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.

Item

http://www.wikidata.org/entity/Q51111145

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A case-based discussion of cli ...... ruxolitinib for myelofibrosis.

@en

A case-based discussion of cli ...... ruxolitinib for myelofibrosis.

@nl

type

Item

label

A case-based discussion of cli ...... ruxolitinib for myelofibrosis.

@en

A case-based discussion of cli ...... ruxolitinib for myelofibrosis.

@nl

prefLabel

A case-based discussion of cli ...... ruxolitinib for myelofibrosis.

@en

A case-based discussion of cli ...... ruxolitinib for myelofibrosis.

@nl

P1476

A case-based discussion of cli ...... ruxolitinib for myelofibrosis.

@en

P2093

Ashish Bajel

http://www.w3.org/2001/XMLSchema#string

Cecily Forsyth

http://www.w3.org/2001/XMLSchema#string

David M Ross

http://www.w3.org/2001/XMLSchema#string

Kate Burbury

http://www.w3.org/2001/XMLSchema#string

Lindsay Dunlop

http://www.w3.org/2001/XMLSchema#string

P Joy Ho

http://www.w3.org/2001/XMLSchema#string

Simon Durrant

http://www.w3.org/2001/XMLSchema#string

P2860

Pulmonary hypertension in patients with chronic myeloproliferative disorders

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.

Ruxolitinib Enhances Platelet Production in Patients With Thrombocytopenic Myelofibrosis.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.

Practical management of myelofibrosis with ruxolitinib.

P304

262-268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IMJ.13341

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrew C Perkins

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28260257

http://www.w3.org/2001/XMLSchema#string